Is MEDXF or FCPT a better dividend investment in 2026?

MEDXF currently yields 89.29% with a 5% 5-year dividend growth rate. FCPT yields 6.05% with 5% growth. The better choice depends on your goal: MEDXF offers higher current income.

What is the dividend yield difference between MEDXF and FCPT?

MEDXF has a forward dividend yield of 89.29% ($2.00/share annually). FCPT yields 6.05% ($1.43/share annually). The yield gap is 83.24 percentage points.

Home › Compare › MEDXF vs FCPT

MEDXF vs FCPT: Dividend Comparison 2026

MEDXF yields 89.29% · FCPT yields 6.05%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MEDXF wins by $2.44M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MEDXF

● Live price

89.29%

Share price

$2.24

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.49M

Annual income

$776,963.67

Full MEDXF calculator →

FCPT

● Live price

6.05%

Share price

$23.65

Annual div

$1.43

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$49.1K

Annual income

$5,775.28

Full FCPT calculator →

Portfolio growth — MEDXF vs FCPT

📍 MEDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MEDXF	FCPT
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MEDXF + FCPT cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MEDXF pays

FCPT pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDXF

Annual income on $10K today (after 15% tax)

$7,589.29/yr

After 10yr DRIP, annual income (after tax)

$660,419.12/yr

FCPT

Annual income on $10K today (after 15% tax)

$514.49/yr

After 10yr DRIP, annual income (after tax)

$4,908.99/yr

At 15% tax rate, MEDXF beats the other by $655,510.13/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDXF + FCPT for your $10,000?

MEDXF: 50%FCPT: 50%

100% FCPT50/50100% MEDXF

Portfolio after 10yr

$1.27M

Annual income

$391,369.47/yr

Blended yield

30.84%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

MEDXF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

0.9

Piotroski

5/9

FCPT

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$27.00

+14.2% upside vs current

Range: $25.00 — $29.00

Altman Z

1.4

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDXF buys

FCPT buys

No recent congressional trades found for MEDXF or FCPT in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMEDXFFCPT

Forward yield	89.29% ✓	6.05%
Annual dividend / share	$2.00 ✓	$1.43
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$2.49M	$49.1K ✓
Annual income after 10y	$776,963.67 ✓	$5,775.28
Total dividends collected	$2.19M	$24.1K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Hold	Hold

Year-by-year: MEDXF vs FCPT ($10,000, DRIP)

Year	MEDXF Portfolio	MEDXF Income/yr	FCPT Portfolio	FCPT Income/yr	Gap
1← crossover	$19,629	$8,928.57	$11,401	$700.92	+$8.2K → MEDXF
2	$37,382	$16,378.98	$13,064	$864.84	+$24.3K → MEDXF
3	$69,150	$29,152.23	$15,051	$1,072.48	+$54.1K → MEDXF
4	$124,390	$50,399.46	$17,442	$1,337.22	+$106.9K → MEDXF
5	$217,827	$84,729.38	$20,340	$1,677.08	+$197.5K → MEDXF
6	$371,743	$138,667.67	$23,880	$2,116.57	+$347.9K → MEDXF
7	$618,933	$221,167.77	$28,241	$2,689.36	+$590.7K → MEDXF
8	$1,006,401	$344,142.93	$33,660	$3,442.07	+$972.7K → MEDXF
9	$1,599,826	$522,977.14	$40,456	$4,439.95	+$1.56M → MEDXF
10	$2,488,777	$776,963.67	$49,063	$5,775.28	+$2.44M → MEDXF

MEDXF vs FCPT: Complete Analysis 2026

MEDXF — Stock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Full MEDXF Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →

📬

Get this MEDXF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDXF vs SCHD MEDXF vs JEPI MEDXF vs O MEDXF vs KO MEDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.